// App-Quantinova.ai

4165 : Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Researchers

Presenter

  • Kami Maddocks

Principal Investigators

  • John Pagel

  • Susan -Brien

  • John C. Byrd

  • Scott Stromatt

  • Farrukh T Awan

Medical Centers

  • Emergent Product Development, Seattle, WA

  • The James Cancer Hospital Ohio State University, Columbus, OH

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Ohio State University Wexner Medical Center, Columbus, OH

  • Georgia Regents University, August, GA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Deep vein thrombosis

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

Biomarkers

  • Nucleoside diphosphate kinase A

  • Src homology region 2 domain-containing phosphatase-1

Drug/Treatment

  • Otlertuzumab

  • Alemtuzumab

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved